Payment overview · 2025
General Payments
$2,542.54
134 reported records · 28 companies
Healthcare provider profile · identity verified
Michael C Wallace, MD
Allopathic & Osteopathic Physicians|Family Medicine · MEMPHIS, TN · NPI 1932192556
Verified facts
What the public records show
CMS Open Payments records show Michael C Wallace, MD received $2,542.54 in general payments during 2025 across 134 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $557.29 | 21.9% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $352.22 | 13.8% | 22 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $221.70 | 8.7% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $180.65 | 7.1% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $174.41 | 6.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.57 | 5.9% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.60 | 4.0% | 5 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $96.93 | 3.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.85 | 3.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.78 | 2.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.85 | 2.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.20 | 1.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $46.71 | 1.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.49 | 1.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.42 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.64 | 1.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.54 | 1.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $32.01 | 1.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.68 | 1.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.10 | 1.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25.45 | 1.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.41 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.80 | 0.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $19.39 | 0.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.30 | 0.7% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $15.97 | 0.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.50 | 0.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,542.54 | 134 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $302.22 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $267.30 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $228.03 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $180.77 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $180.65 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $158.07 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.28 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $102.28 | 6 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $96.93 | 4 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $96.93 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.06 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.23 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.78 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.78 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.34 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $64.73 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.00 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.00 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.00 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.56 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $46.71 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.64 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.87 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 110 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
110 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 117 |
| Alprazolam | Alprazolam | 310 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 90 |
| Methylprednisolone | Methylprednisolone | 284 | 183 |
| Losartan Potassium | Losartan Potassium | 268 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 219 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 62 |
| Gabapentin | Gabapentin | 199 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 56 |
| Montelukast Sodium | Montelukast Sodium | 189 | 55 |
| Fluconazole | Fluconazole | 181 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 95 |
| Fenofibrate | Fenofibrate | 175 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 63 |
| Allopurinol | Allopurinol | 160 | 55 |
| Metformin Hcl Er | Metformin Hcl | 160 | 52 |
| Omeprazole | Omeprazole | 145 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 141 | 50 |
| Meloxicam | Meloxicam | 140 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 45 |
| Metformin Hcl | Metformin Hcl | 137 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 27 |
| Famotidine | Famotidine | 121 | 45 |
| Potassium Chloride | Potassium Chloride | 115 | 37 |
| Furosemide | Furosemide | 114 | 40 |
| Lisinopril | Lisinopril | 113 | 36 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 110 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 109 | 79 |
| Tramadol Hcl | Tramadol Hcl | 100 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 68 |
| Ezetimibe | Ezetimibe | 94 | 33 |
| Trazodone Hcl | Trazodone Hcl | 94 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 92 | 26 |
| Spironolactone | Spironolactone | 90 | 29 |
| Clonazepam | Clonazepam | 89 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 25 |
| Azelastine Hcl | Azelastine Hcl | 81 | 37 |
| Azithromycin | Azithromycin | 81 | 68 |
| Ondansetron Odt | Ondansetron | 79 | 44 |
| Mirtazapine | Mirtazapine | 78 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 26 |
| Ozempic | Semaglutide | 74 | 18 |
| Cefdinir | Cefdinir | 71 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 24 |
| Valacyclovir | Valacyclovir Hcl | 71 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 18 |
| Finasteride | Finasteride | 64 | 15 |
| Jardiance | Empagliflozin | 64 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 20 |
| Nystatin | Nystatin | 58 | 24 |
| Simvastatin | Simvastatin | 58 | 20 |
| Eliquis | Apixaban | 57 | 16 |
| Ibuprofen | Ibuprofen | 57 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 19 |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Lorazepam | Lorazepam | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 12 |
| Mupirocin | Mupirocin | 49 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 49 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 13 |
| Bupropion Xl | Bupropion Hcl | 46 | 19 |
| Myrbetriq | Mirabegron | 45 | 11 |
| Pregabalin | Pregabalin | 43 | 14 |
| Risedronate Sodium | Risedronate Sodium | 42 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 14 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 11 |
| Prednisone | Prednisone | 40 | 28 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Carvedilol | Carvedilol | 39 | 17 |
| Cephalexin | Cephalexin | 39 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 22 |
| Levofloxacin | Levofloxacin | 35 | 23 |
| Propranolol Hcl | Propranolol Hcl | 35 | 15 |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | 14 |
| Terazosin Hcl | Terazosin Hcl | 31 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 11 |
| Topiramate | Topiramate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Zaleplon | Zaleplon | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Kerendia | Finerenone | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Nateglinide | Nateglinide | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,542.54 · 134 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, Azstarys, BEYFORTUS, BREZTRI, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, EGRIFTA, FARXIGA, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, Kerendia, Korlym, LINZESS, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, TROGARZO, UBRELVY, VOQUEZNA, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error